XNAS · Healthcare · Biotechnology
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q3 2026 | -0.06 | -0.07 | -16.67% | $0 | ❌ Miss | +2.89% | -6.83% | — |
| 2026-02-10 | Q2 2026 | -0.07 | -0.09 | -28.57% | $0 | ❌ Miss | +5.73% | +0.88% | +9.69% |
| 2025-11-12 |
| Q1 2026 |
| -0.07 |
| -0.11 |
| -57.14% |
| $100,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-09-05 | Q4 2025 | -0.25 | -0.32 | +15.79% | $200,000 | ❌ Miss | — | — | — |
| 2025-02-10 | Q2 2025 | -0.32 | -0.48 | -50.00% | $200,000 | ❌ Miss | -7.31% | +7.60% | +62.28% |
| 2024-09-20 | Q4 2024 | -0.48 | -0.91 | -89.58% | $175,000 | ❌ Miss | -6.09% | +5.58% | +56.85% |
| 2024-05-13 | Q3 2024 | — | -0.71 | — | $0 | — | +3.56% | +18.43% | +40.46% |
| 2024-02-09 | Q2 2024 | — | -2.42 | — | $0 | — | — | — | — |
Showing last 8 quarters.